While most of his twenty-something peers were chasing fun and freedom… 

Our Paradigm colleague Ray was engaged in the scariest battle imaginable -- waging war on cancer.

Spoiler alert: Ray won. And he’s been winning ever since.

If you don’t know him..

Ray’s a respected figure in biotech and medical technology investing. Investors looking for the next big breakthrough that could disrupt modern medicine have long sought after his advice.

But, here’s the thing:

Most people don’t know his origin story -- and how he got his start in biotech investing.

Today we aim to end that. We invited Ray to share his story.

Not just that…

He’s also going to share what he believes could be the biggest medical breakthrough in decades -- a radical tech shift that’s already transformed how companies are treating aggressive diseases like cancer.

It's an opportunity he thinks could dwarf all of his previous biotech successes.

AND…

There’s ONE tiny $500 million company he believes could capture the lion’s share -- and make early investors feel like they robbed Fort Knox.

Check it out below.

Read on.

When I was 20 years old, I got the kind of news that no young person wants to hear...

I had cancer. Hodgkin's lymphoma to be exact.

The hair loss, the radiation burns, the relentless nausea - it was one of the hardest things I've ever gone through. If I'm being honest, there were times I didn't think I'd make it.

You see, back in the 1990s when I was diagnosed, surviving Hodgkin's lymphoma wasn't even a 50/50 proposition. The treatments were grueling and the odds of beating this disease were stacked against you.

Fortunately, advancements in medical technology over the years turned my fate around. The radiation and chemotherapy regimens that were still cutting-edge at the time ultimately saved my life. 

I'll never forget how fortunate I was to have access to those breakthrough cancer treatments when I did. If I had been diagnosed just 10 years earlier, before those advancements, I may not be here today.

That life-changing experience sparked my obsession with medical breakthroughs and led me to where I am today - hunting for the next big investment opportunities in healthcare technology.

And I've never been more excited than I am right now…

Cancer is Finished

You see, a brand new technology is emerging out of Silicon Valley that is poised to revolutionize how we treat cancer and so many other diseases. It's going to save millions of lives and early investors will have a shot at landing a life-changing payday.

I'm talking about artificial intelligence (AI).

Companies are now using advanced forms of AI to discover and develop entirely new drugs at lightning-fast speed. This "generative AI" is able to dream up potential new therapeutic compounds, far faster than any human researcher could.

AI is then used to refine and optimize these computer-generated drug candidates, getting them ready for real-world trials in a fraction of the normal time.

The implications for treating aggressive diseases like cancer are profound.

Computer models are able to analyze mountains of data - genetic profiles, scientific studies, patient histories - and find ideal drug targets and candidates that human researchers may have overlooked or given up on.

Already, dozens of drugs discovered and optimized by AI are in clinical trials for all sorts of cancers, rare diseases, autoimmune disorders and more. And the early results look incredibly promising.

The Tiny $500 Million Behemoth

Using AI, companies will be able to get new life-saving drugs into clinical trials at warp speed. The success rates in those trials will soar as AI optimizes trial conditions and targets only those patients predisposed to benefitting.

It's a game-changer, an inflection point in humanity's fight against disease. Never before have we had a tool as powerful as AI to aid us in that fight.

And there's one little AI healthcare company at the forefront of this revolution that you need to know about today...

This tiny $500 million firm was one of the first to apply advanced AI for drug discovery. Its breakthrough software platform is able to take in massive datasets and quickly surface ideal drug targets and candidates.

The AI then takes those candidates through rapid iteration and refinement - checking for safety, optimizing for efficacy and precision targeting.

Big pharmaceutical giants have already handed this company millions to license access to its AI drug discovery engine. Several early-stage AI-discovered drug candidates are already entering clinical trials for cancers and other diseases.

With a BIG potential payday (in the billions) from future milestone payments and royalties riding on these AI-optimized drugs, this company is truly a speculator's dream.